Given its role in metastasis, targeting MET could be a promising therapeutic strategy. For example, inhibitors of the MET receptor tyrosine kinase, such as crizotinib, are under investigation for their efficacy in preventing or reducing metastasis. However, the dual role of EMT and MET in cancer complicates this approach, necessitating a nuanced understanding of the context-specific roles these processes play.
